Skip to main
OABI
OABI logo

OmniAb Inc (OABI) Stock Forecast & Price Target

OmniAb Inc (OABI) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OmniAb Inc has demonstrated a positive financial trajectory, reporting revenues of $4.2 million for 1Q25, which reflects a 9% increase year-over-year. The company has also reduced its net losses to $18.2 million, equivalent to ($0.17) per share, compared to a loss of $19.0 million or ($0.19) per share in the previous year. Anticipated near- and long-term research and development catalysts, combined with a solid balance sheet, position the company favorably for future growth.

Bears say

OmniAb Inc's stock has experienced a decline since its November 2022 merger with Avista Public Acquisition Corporation II, influenced by negative market trends affecting both similar mergers and established biotech companies. The company's guidance indicates an operating cash burn for the current year that is projected to be lower than that of 2024, which raises concerns about its cost management and financial sustainability in the near term. Overall, these factors contribute to a negative outlook regarding the company's stock performance amidst challenging market conditions.

OmniAb Inc (OABI) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OmniAb Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OmniAb Inc (OABI) Forecast

Analysts have given OmniAb Inc (OABI) a Strong Buy based on their latest research and market trends.

According to 3 analysts, OmniAb Inc (OABI) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OmniAb Inc (OABI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.